Zydus Lifesciences Limited has achieved a major milestone with its first-ever approval from the National Medical Products Administration (NMPA), China. The company received the green light for Venlafaxine Extended-Release (ER) Capsules in 75 mg and 150 mg strengths.
Venlafaxine ER Capsules are prescribed for the treatment of Major Depressive Disorder (MDD), Generalised Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD). The medication works by helping restore the balance of serotonin and norepinephrine in the brain, thereby improving mood and reducing symptoms of anxiety.
These capsules will be manufactured at Zydus’ state-of-the-art facility in Moraiya, Ahmedabad. This marks Zydus’ entry into the Chinese market, strengthening its global footprint in the central nervous system (CNS) therapeutic segment.
With this approval, Zydus Lifesciences continues to expand its international presence and reaffirm its commitment to bringing quality and affordable healthcare solutions to patients across the world.
